Today’s AI Top Pick: ZTS

Zoetis is the cleanest multi-timeframe setup in the pool that also passes the fundamental screen with room to spare. All four timeframes are available and all four point up: 1h fc_long +14.23%, 4h fc_short/mid/long +33.39%/+48.75%, 1d +16.18%/+47.12%/+63.18%, and weekly a massive +24.33%/+78.32%/+108.47%. Bullish_prob is 1.0 and near_term_bullish is 0.8 — this isn't a single-bar outlier, it's the entire ladder confirming. Crucially, ZTS is NOT extended on the timeframe that matters most. Weekly position_in_21bar_range is 4.91% with a -37.17% drawdown from the weekly high — a deeply depressed animal health blue-chip, not a chase. The 1h/4h are at the upper end of their intraday ranges (100/85), so intraday consolidation is possible, but the swing setup is a mean-reversion of a beaten-down quality name, not a breakout being bought at highs. Fundamentals reinforce the tape: fwdPe 10.34, PEG 1.37 (inside the ≤1.5 screen), ROE 67.01%, operating margin 37.57%, profit margin 27.79%, debtEq 2.86 (manageable for a cash-generative pharma), recom 1.95 (buy), targetUpsidePct 42.6%. This is a fortress-margin franchise trading like a broken-growth story after a -48.72% year and -39.44% YTD — the exact 'undervalued emerging' profile the screen was built for. News check: the Neogen genomics deal is under Australian regulatory review (minor, deal-specific, not company-wide), and there's a weight-loss-drugs-for-pets narrative piece — neither is a thesis breaker. Compare that to FUTU (DOJ probe + class actions — hard pass on #1), HDB (CEO reappointment delay + weak margins), PDD (EU AliExpress fine drags China e-comm sentiment), and DCBO/BZ (short/mid forecasts negative). Waiting risks missing a weekly reversal from a deeply oversold base; today's slight intraday extension is not enough to defer entry — scale in.